“We are thrilled to introduce our new office in London. As our team grows and our product line expands, we are marching towards the company’s goal to provide the most effective biologic formulations for human and veterinary medicine”.
Robert N. Jordan /CEO of Vetirus
Vetirus, based in Naples, FL opened offices in London at the London BioScience Innovation Center, in the Royal Veterinary College, just ahead of the highly anticipated release of their natural biologic formulations, MitoPak (for humans) and Exenias (for cats and dogs).
Vetirus Pharmaceuticals is a next generation Pharma company with an intense focus on Natural biologic, Entheogenic, and Mycogenic therapies for the human and veterinary market.
Vetirus has several products in the human market. One for the treatment of Periodontal disease and the second supporting the mitigation of the inflammatory cascade at the mitochondrial level. Vetirus has several pipeline drugs in development and will further this in their new European headquarters.
In the veterinary marketplace, Vetirus has developed a therapy for sarcopenia and cachexia in felines and canines, set for a Q4 2023 rollout.
“We are thrilled that we have chosen to expand our operations to London," said Robert Jordan, CEO of Vetirus. "As a hotbed of creativity and innovation, with a strong mix of growth capital and world-class talent, London is an ideal place for us to grow and scale.”